Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Barceló-Vidal, Jaime
• dc.contributor.author Echeverría Esnal, Daniel
• dc.contributor.author Carballo Martínez, Núria
• dc.contributor.author De Antonio Cuscó, Marta
• dc.contributor.author Fernández-Sala, Xènia
• dc.contributor.author Navarrete Rouco, Maria Eugenia
• dc.contributor.author Colominas-González, Elena
• dc.contributor.author Luque Pardos, Sònia
• dc.contributor.author Fuster-Esteva, M.
• dc.contributor.author Domingo, Laia
• dc.contributor.author Sala Serra, Maria
• dc.contributor.author Duran Jordà, Xavier, 1974-
• dc.contributor.author Grau Cerrato, Santiago
• dc.contributor.author Ferrández, Olivia
• dc.date.accessioned 2023-04-05T06:15:51Z
• dc.date.available 2023-04-05T06:15:51Z
• dc.date.issued 2022
• dc.description.abstract Introduction: Drug-related problems (DRP) are events or circumstances in which drug therapy does or could interfere with desired health outcomes. In December 2019, a new coronavirus, SARS-CoV-2, appeared. Little knowledge about this type of infection resulted in the administration of various drugs with limited use in other pathologies. Evidence about DRP in patients with COVID-19 is lacking. Objective: The aim of the present study is to describe identified cases of DRP and those drugs involved in the first wave of patients with COVID-19, and evaluate associated risk factors. Material and methods: Observational, retrospective study performed in a tertiary university hospital between 14th March 2020 and 31 May 2020 (corresponding to the first COVID-19 wave). We recruited patients admitted during the study period. Exclusion criteria included age < 18 years; admission to critically ill units; and care received either in the emergency room, at-home hospitalization or a healthcare center. Results: A total of 817 patients were included. The mean age was 62.5 years (SD 16.4) (range 18-97), and 453 (55.4%) were male. A total of 516 DRP were detected. Among the patients, 271 (33.2%) presented at least one DRP. The mean DRP per patient with an identified case was 1.9. The prevailing DRPs among those observed were: incorrect dosage (over or underdosage) in 145 patients (28.2%); wrong drug combination in 131 (25.5%); prescriptions not in adherence to the then COVID-19 treatment protocol in 73 (14.1%); prescription errors due to the wrong use of the computerized physician order entry in 47 (9.2%); and incorrect dosage due to renal function in 36 (7%). The logistic regression analysis showed that patients who received only prescriptions of antibacterials for systemic use (J01 ATC group) faced a higher likelihood of experiencing a DRP (OR 2.408 (1.071-5.411), p = 0.033). Conclusion: We identified several factors associated with an increased risk of DRPs, similar to those reported in other pre-pandemic studies, including a prolonged length of stay, higher number of prescribed drugs and antimicrobial administration. The relevance of pharmacists and tools like pharmacy warning systems can help prevent, identify and resolve DRP efficiently.
• dc.format.mimetype application/pdf
• dc.identifier.citation Barceló-Vidal J, Echeverría-Esnal D, Carballo N, De Antonio-Cuscó M, Fernández-Sala X, Navarrete-Rouco ME, Colominas-González E, Luque S, Fuster-Esteva M, Domingo L, Sala M, Duran X, Grau S, Ferrández O. Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic. Front Pharmacol. 2022 Nov 24;13:993158. DOI: 10.3389/fphar.2022.993158
• dc.identifier.doi http://dx.doi.org/10.3389/fphar.2022.993158
• dc.identifier.issn 1663-9812
• dc.identifier.uri http://hdl.handle.net/10230/56409
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Pharmacol. 2022 Nov 24;13:993158
• dc.rights © 2022 Barceló-Vidal, Echeverría-Esnal, Carballo, De Antonio-Cuscó, Fernández-Sala, Navarrete-Rouco, Colominas-González, Luque, Fuster-Esteva, Domingo, Sala, Duran, Grau and Ferrández. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword SARS-CoV-2
• dc.subject.keyword Antiinfective agents
• dc.subject.keyword Drug medication safety
• dc.subject.keyword Drug-related problem (DRP)
• dc.subject.keyword Medication error
• dc.subject.keyword Medication related problem
• dc.subject.keyword Pharmaceutical care
• dc.title Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion